Stockreport

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]

Olema Pharmaceuticals, Inc.  (OLMA) 
PDF Initiated OPERA-01 pivotal Phase 3 monotherapy trial in Q4 2023; top-line results expected in 2026 60-patient Phase 2 studies in combination with each of ribociclib a [Read more]